Form 4 for KLRS Kalaris Therapeutics, Inc.
Accepted 2022-11-21 00:00:00 ET · period of report 2022-11-18 · accession 0000899243-22-036553 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-11-21 | 2022-11-18 | KLRS | Brainard Diana | CEO, Dir | S - Sale | $7.27 | -4,515 | 633.0K | -0.7% | -$32.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-18 | S | D | 4,515 | $7.27 | 633,033 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.23 to $7.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |